Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt

EU orphan designation number: EU/3/16/1692   
Active ingredient: 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt
Indication: Treatment of idiopathic pulmonary fibrosis
Sponsor: Vicore Pharma AB
c/o Astra Zeneca, Pepparedsleden 1, 431 83 Mölndal, Sverige

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/07/2016 Orphan designation EMA/OD/046/16 (2016)4677 of 14/07/2016